用维生素D3和维生素A补充剂可以减轻帕金森病症在利的小鼠模型中
Mujittapha Umar Sirajo1, John C Oyem2, Mohammed Ibrahim Badamasi3
1Anatomy Unit, Department of Physiotherapy, School of Basic Medical Sciences, Skyline University, Nigeria; Department of Human Anatomy, Faculty of Basic Medical Science, Bayero University Kano, Nigeria.
Journal of chemical neuroanatomy
|December 1, 2023
概括
维生素D3和维生素A补充剂在帕金森症小鼠模型中显著改善了运动功能并减少了神经退行. 这种联合治疗可能有助于减缓运动缺陷的进展.
科学领域:
- 神经科学是一个神经科学.
- 营养神经科学 营养神经科学
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森症与运动缺陷有关.
- 维生素D3 (Vit D3) 补充剂可能减轻帕金森症.
- 维生素A (Vit A) 可能优化维生素D3的功能.
研究的目的:
- 为了研究维生素D3和维生素A在帕金森症的哈洛佩里多尔诱导的小鼠模型中同时使用的疗效.
- 为了确定组合维生素补充剂是否比单个补充剂或烯胺更有效.
主要方法:
- 三十六只成年雄性小鼠被分成六组.
- 组包括对照组,哈洛佩里多尔诱导的帕金森症模型,以及接受哈洛佩里多尔与维生素D3,维生素A,维生素D3+维生素A或烯素的组.
- 进行了神经行为测试,生化和组织形态学分析.
主要成果:
- 哈洛佩里多尔诱导的帕金森症小鼠表现出显著的运动衰退和神经退行.
- 联合维生素D3和维生素A治疗显著改善了运动活动.
- 维生素D3+维生素A还减轻了氧化应激和神经退行性特征,与单独的维生素治疗或烯胺相比.
结论:
- 同时服用维生素D3和维生素A可以防止小鼠模型中的帕金森症特征.
- 补充维生素D3+维生素A是一种减缓运动缺陷发作和进展的潜在策略.
相关概念视频
01:24Parkinson's Disease: Treatment
276
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
276
01:15Parkinson's Disease: Overview
557
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
557